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 4 
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 7 
Background: Targeted intervention for subgroups is a promising approach for the management 8 
of patellofemoral pain.  9 
Hypothesis: Treatment designed according to subgroups improves clinical outcomes in 10 
patients unresponsive to multimodal treatment. 11 
Study Design: A prospective crossover intervention. 12 
Level of Evidence: Level III 13 
Methods: PFP patients (n=61, mean age: 27±9 years) were enrolled. PFP patients received 14 
standard multimodal treatment three times a week for 6 weeks. Patients not responding to 15 
multimodal treatment were then classified into one of 3 subgroups “strong”, “weak and tight” 16 
and “weak and pronated foot” using six simple clinical tests. They subsequently were 17 
administered a further 6 weeks of targeted intervention designed according to subgroup 18 
characteristics. Visual Analog Scale (VAS), Perception of Recovery Scale (PRS), EQ-5D-5L, 19 
and S-LANSS were used to assess pain, knee function and quality of life before and after the 20 
interventions.  21 
Results: 36% of the patients (21 patients) demonstrated recovery following multimodal 22 
treatment.  However, over 70% (29 patients) of these non-responders demonstrated recovery 23 
after targeted treatment. The VAS, PRS, S-LANSS, and EQ-5D-5L scores improved 24 
significantly after targeted intervention compared to after multimodal treatment (p<0.001). The 25 
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VAS score at rest was significantly lower in the weak and pronated foot, and weak and tight 26 
subgroups (p=0.011, p=0.008) respectively. Post-treatment pain intensity on activity was 27 
significantly lower in the “strong” subgroup (p=0.006).  28 
Conclusion: Targeted treatment designed according to subgroup characteristics improves 29 
clinical outcomes in patients unresponsive to multimodal treatment.  30 
Clinical Relevance: Targeted intervention could be easily implemented following six simple 31 
clinical assessment tests to subgroup patients into one of three subgroups (strong, weak and 32 
tight, weak and pronated foot). Targeted interventions applied according to the characteristics 33 
of these subgroups have more beneficial treatment effects than a current multimodal treatment 34 
program. 35 
 36 
Key words: Rehabilitation, knee injuries, patella, treatment outcome, pain perception 37 
 38 
INTRODUCTION 39 
Patellofemoral pain (PFP) is a chronic musculoskeletal problem that causes persistent anterior 40 
knee pain.2,3,6,8,14,15,20,21,25,26,32,33,49 Despite its widespread use in clinics, it is difficult to suggest 41 
that the current multimodal treatment approach leads to successful outcomes in the majority of 42 
patients with PFP, only 46% of patients’ knees were pain free at discharge.2 This indicates that 43 
over half of PFP patients do not respond to treatment and may continue their lives with chronic 44 
anterior knee pain.  45 
Identification of the factors leading to these low treatment success rates has consistently been a 46 
priority of previous International Patellofemoral Pain Research Retreats.4,10,12,52 The most 47 
important factor affecting the success of treatment that has emerged is that patients have a 48 
variety of musculoskeletal and biomechanical differences. The current multimodal treatment, 49 
therefore, may not affect the heterogeneous PFP patient population with the same efficiency. 50 
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Clinically subgrouping PFP patients and delivering targeted treatments has been strongly 51 
recommended for future investigations of patellofemoral pain treatment from the International 52 
Patellofemoral Pain Research Retreats.4,12,52 An overview of previously published PFP 53 
subgroups and the methods used to derive subgroups in PFP identified patients with PFP.39 54 
They exhibit different anthropometric and biomechanical characteristics and do not form a 55 
homogeneous group. There are 3 subgroups in the PFP population: “strong”, “weak and tight” 56 
and “weak and pronated foot”.38 The purpose of this study was to assess the clinical outcomes 57 
of targeted treatments designed according to the characteristics of the three subgroups of PFP 58 
patients.38 The hypotheses were that the assessment and subgroup classification is clinically 59 
feasible, and that targeted treatments designed according to the characteristics of the three 60 
subgroups of PFP patients would show clinical benefits over and above a multimodal 61 
intervention. 62 
METHOD 63 
Design  64 
A prospective crossover intervention study design was used (Figure 1).  65 
Participants 66 
Patients aged between 18 and 40 attending a physiotherapy outpatient clinic at a University 67 
Hospital with a clinical diagnosis of patellofemoral pain were approached for eligibility in this 68 
study. Eligibility criteria were based on previously defined PFP criteria.7,38,47 Subjects were 69 
excluded if they had any of the following: previous knee surgery, clinical evidence of 70 
ligamentous instability and/or internal derangement, a history of patellar subluxation or 71 
dislocation, joint effusion, true knee joint locking and/or giving way, bursitis, patellar or 72 
iliotibial tract tendinopathy, Osgood Schlatter’s disease, Sinding-Larsen Johansson Syndrome, 73 
muscle tears or symptomatic knee plicae, serious co-morbidity which would preclude or affect 74 
compliance with the assessment, or were pregnant. 75 
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 76 
Subgroup Classification Method 77 
Quadriceps and Hip Abductor muscle strength 31, Patellar glide test44,54, Quadriceps length53, 78 
Gastrocnemius length53, and Foot posture index36 assessments were performed to classify all 79 
consenting patients into one of three subgroups (strong, weak and tight, weak and pronated 80 
foot) using the algorithm derived from the work by Selfe et al.38 81 
 82 
Intervention 83 
Multimodal Treatment 84 
The multimodal treatment program was designed based on the usual exercise and modalities 85 
used in local clinics.20,21,32,49 All patients received standard, supervised, 60 min multimodal 86 
treatment three times a week for 6 weeks. Table 1 shows the details of the multimodal 87 
rehabilitation program. 88 
Targeted Treatment 89 
Patients who did not respond to multimodal treatment were assigned to one of the treatment 90 
groups “strong”, “weak and tight”, and “weak and pronated foot”. They then followed a further 91 
6 weeks, 45 min targeted intervention program administered three times a week. The targeted 92 
treatment program was designed according to the key deficits identified in each patient by the 93 
subgrouping clinical assessment tests. The patients in the “strong” subgroup had no muscle 94 
strength deficit therefore, the intervention program for this subgroup was targeted at improving 95 
neuromuscular control and coordination ability using proprioceptive exercises such as 96 
progressive balance exercises, and knee braces46,47 which have been shown to offer 97 
improvements in movement control in patients with PFP,41 reductions in patellofemoral 98 
reaction forces44 and have been shown to reduce pain at 6 and 12 months during a PFP 99 
rehabilitation program.48 In the “weak and tight” subgroup, the exercise program consisted of 100 
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Closed Kinetic Chain (CKC) muscle strengthening and stretching, and weight management 101 
advice, as a larger body mass index was identified as a potentially relevant clinical feature in 102 
this subgroup.38 In the “weak and pronated foot” subgroup, muscle weakness and abnormal foot 103 
alignment were identified as the key factors. Therefore, the intervention program included CKC 104 
strengthening exercises and foot orthoses.5,24 Table 2 shows the details of each of the specific 105 
targeted intervention programs.   106 
Outcome measures 107 
Pain during activity measured using the Visual Analog Scale (VAS) was the primary outcome 108 
measure of this study 19. Activity was specified by patients. 109 
The Perception of Recovery Scale was measured using a 7-point Likert scale ranging from 110 
“completely recovered” to “worse than ever”. Patients were classified as “recovered” if they 111 
rated themselves as “completely recovered” or “strongly recovered”. Patients rating themselves 112 
in one of the other five categories from “slightly recovered” to “worse than ever" were 113 
categorised as “not recovered”.35 114 
The EQ-5D-5L was used as a self-reported generic measure of health and quality of life. 115 
Patients rated their overall health on the day of the interview on a 0–100 hash-marked, vertical 116 
visual analogue scale (EQ-5D-5L-VAS). A higher EQ-5D-5L-VAS score indicating better 117 
health status.22 118 
Neuropathic Pain was measured using The Self-Administered Leeds Assessment of 119 
Neuropathic Symptoms and Signs (S-LANSS) questionnaire. The S-LANSS comprises a 5-120 
item questionnaire regarding pain symptoms and two items for clinical signs involving self-121 
administered sensory tests for the presence of allodynia and decreased sensation to pinprick. 122 
This was used to discriminate the small number of patients who may have neuropathic knee 123 
pain from those with nociceptive pain.42 The possible scores range from 0 to 24, with a score 124 
of 12 or greater considered to be suggestive of neuropathic pain.28 Finally, a single leg hop test 125 
  
6 
 
was used to determine functional performance.1 Distance was measured from toe to heel and 126 
the mean score of three repetitions was recorded.  127 
Data analysis 128 
A sample size calculation was performed based on the minimal detectable change on the pain 129 
VAS. Data from a previous study indicates that the VAS scores in patients with PFP was 4.3 ± 130 
1 cm,9 with 30% of the maximum score of the VAS-pain considered to be the detectable change, 131 
the sample size for each treatment subgroup was determined to be 8 patients to achieve a 90% 132 
power at the 0.05 level of significance. Data were not normally distributed when analysed with 133 
the Kolmogorov–Smirnov test Consequently, non-parametric tests were indicated. Therefore 134 
the “Wilcoxon signed rank test” was used to compare pre and post treatment outcomes with an 135 
alpha value of 0.05. In addition, the mean of rank scores, standard errors and Z scores were 136 
reported, along with descriptive statistics to describe the general features of the subjects. All 137 
statistical analysis was conducted using SPSS 21.0.  138 
 139 
RESULTS 140 
Of the 128 patients who were screened, 95 were included in the present study. Of these 61 141 
patients completed the multimodal treatment (Figure 1) (Table 3). Twenty-one patients (36%) 142 
demonstrated recovery following multimodal treatment (Phase I) and were discharged. 40 143 
Patients (64%) not responding to multimodal treatment were administered a further 6 weeks of 144 
targeted intervention designed according to subgroup characteristics (phase 2).  Twenty-nine 145 
(72.5%) patients demonstrated recovery following targeted intervention (phase II) and 11 146 
(27.5%) patients did not respond to either of the treatment approaches (Table 4).  147 
Pain intensity (VAS) at rest and during activity, and Perceived Recovery Scale (PRS), were 148 
significantly improved after targeted intervention (p<0.001) (Table 5). S-LANSS, EQ-5D-5L 149 
and EQ5D-5L-VAS scores were significantly improved following targeted intervention 150 
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compared to pre-targeted treatment scores (p = 0.001, p<0.001, p = 0.02), respectively (Table 151 
5).  152 
Within the three subgroups, the findings showed that PRS score was significantly improved 153 
after targeted treatment compared to pre-targeted treatment levels in the “strong”, “weak and 154 
tight”, and “weak and pronated foot” subgroups (p= 0.005, p= 0.001, p= 0.004) respectively.  155 
VAS pain intensity at rest was also significantly lower after targeted intervention in the “weak 156 
and pronated foot” and “weak and tight” subgroups (p=0.011, p= 0.008) respectively, however 157 
within the “strong” subgroup, no change was seen between pre-treatment and post treatment (p 158 
= 0.245) (Table 6). However, pain intensity during activity was significantly lower after 159 
treatment in the “strong” (p=0.006), the “weak and pronated foot” and “weak and tight” 160 
subgroups; although these reductions were not statistically significant (p=0.059, p= 0.06) 161 
respectively (Table 6).  162 
Other measures including quadriceps length test, S-LANSS, EQ5D-5L, and EQ5D-VAS were 163 
significantly improved in the “weak and tight” subgroup. S-LANSS, EQ5D-5L, and patellar 164 
mobility were significantly improved in the “weak and pronated foot” subgroup. In the “strong” 165 
group only gastrocnemius length was significantly different between pre- and post-targeted 166 
treatment (p=0.03). Results for outcome measures are shown in Table 7. 167 
 168 
DISCUSSION  169 
The results of our study suggest that the TIPPs subgroups and the algorithm used to classify 170 
PFP patients as "strong", "weak and tight", "weak and pronated foot" 38 is valid and clinically 171 
implementable. The findings from this study were in agreement with previous work13 that 172 
reported differential response patterns in outcomes at 12 months in their subgroups. This 173 
suggests that targeted interventions based on subgroups, provides an important development in 174 
the treatment strategy for patients with PFP.4,52 175 
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The “strong” subgroup demonstrated a poor response to multimodal treatment but a a 176 
significant improvement after targeted treatment was observed. This finding is consistent with 177 
Greuel et al.18 and Gallina et al.17 who both reported results confirming that motor control of 178 
the quadriceps is problematic in some PFP patients. One explanation for this is improved 179 
neuromuscular control in patients classified as “strong”. Since these patients already 180 
demonstrated relatively high quadriceps muscle torque, targeted intervention was delivered 181 
focusing on progressive development of motor control on unstable surfaces instead of 182 
conventional muscle strength exercises. Given that quadriceps strength did not change as a 183 
result of the targeted intervention, these progressive balance exercises and patellar bracing has 184 
improved motor control and stability.41 In addition, bracing may reduce patellofemoral forces 185 
during activities of daily living and sporting tasks44 and improvements within rehabilitation 186 
protocols.48 This was reflected in the improvement in the other pain related parameters, 187 
However, since the average pre-treatment VAS pain level at rest in this subgroup was already 188 
low a decrease from 1.8 to 0.7 has minimal clinical relevance. 189 
Clinically the “weak and tight” subgroup appeared to be the most responsive group to treatment 190 
overall with a relatively even split of 52% responding to multimodal treatment and all of the 191 
remaining patients responding to targeted intervention. This finding was not surprising as 192 
multimodal treatment routinely includes strengthening and stretching exercises. However, 193 
closer analysis of the outcomes in the "weak and tight" subgroup suggest that although patients’ 194 
perception of recovery improved, the VAS activity pain intensity was not significantly 195 
decreased after targeted treatment in this subgroup. Considering muscle weakness is the main 196 
issue in this subgroup, the probable cause of this unexpected finding is persistent inability to 197 
compensate patellofemoral loads especially during relatively high level activities of daily life 198 
such as ascending/descending stairs even after the targeted treatment. Targeted intervention 199 
consisting of functional strengthening may still be insufficient for high level activities of daily 200 
  
9 
 
living which demand considerable muscular activity, although it caused approximately a 30% 201 
increase in muscle torque and a significant improvement in perception of recovery in this 202 
subgroup.  203 
Findings from the “weak and pronated foot” subgroup suggest that targeted treatment including, 204 
foot orthoses and pain free strengthening exercises was also successful in terms of perception 205 
of recovery and VAS pain on rest. Although the same improvement was not observed in VAS 206 
pain during activity. One explanation for this could be the indirect effect of the foot orthoses 207 
on the knee as the patients showed no improvement in strength after targeted treatment. 208 
Moreover, optimum correction is very difficult to determine during the intervention of foot 209 
orthoses. Special single physiotherapy interventions or combining interventions for patellar 210 
taping, mobilisation or manual therapy may have beneficial effects on pain related functional 211 
symptoms in PFP.11,30,34 However, the therapeutic effects of these applications remain limited 212 
because PFP patients exhibit a wide variety of structural features and biopsychosocial 213 
differences. The biomechanical and anthropometric characteristics of patients were not similar. 214 
Foot pronation, for example, was noticeably high in some patients, while some had neutral foot 215 
alignment. Similarly, quadriceps muscle strength, which is a predisposing factor or a most 216 
common symptom in previous studies8,54 has been high in some patients with the remainder 217 
having considerable muscle weakness. Therefore, specific applications such as foot orthoses, 218 
knee braces, tape, and even exercises may not be required by every patient.  219 
The functional hop test is often used in clinics to measure functional capability.51 Considering 220 
that there was no increase in quadriceps muscle strength in the “weak and pronated foot”, and 221 
“strong” subgroups, an improvement in the hop test scores was not expected.   222 
Due to the methodological design of this study, patients received 6 weeks of multimodal 223 
treatment before 6 weeks of targeted treatment with no intervening washout period. This is a 224 
study limitation since the cumulative effects of the previous treatment (multimodal) were 225 
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ignored. Therefore, the observed difference in some parameters could be the result of regression 226 
to the mean. 227 
CONCLUSION 228 
Both the TIPPs assessment and subgroup classification algorithm are clinically feasible that 229 
those with PFP are not a homogeneous group, and have biomechanical and structural 230 
differences.  231 
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Table 1. Multimodal Treatment Program 383 
 384 
 385 
MODALITY APPLICATION TYPE 
Thermotherapy Cold packs /20 min 
Transcutaneous Electrical Neural Stimulation (TENS) Conventional mode-20 min   
50-100Hz, 20-60 pulse/sec 
Therapeutic Ultrasound (US) 1 Watt/cm² - 5 min/ around knee joint 
Hamstring/tensor fascia lata/ iliotibial band stretching  30sn/5 rep 
Isometric quadriceps strengthening 
 
10 rep x 3 set 
Isometric hip adductor strengthening 
 
10 rep x 3 set 
OKC knee extension exercise 3 sets of patients’ 8-10 RM, in painless ROM 
OKC Hip adductor exercise side lying/ 3 sets of patients’ 8-10 RM 
Home based exercise program*  
RM: Repetition Maximum, rep: repetition, ROM: Range of motion, OKC: Open kinetic chain 386 
*Home based exercise program included the same applications except TENS, NMES, US 387 
 388 
 389 
Table 2. Targeted treatment program 390 
 391 
STRONG SUBGROUP 
Progressive balance/proprioception exercises Standing on one leg on wobble board  
3 sets of 1 min exercise each leg  
1-3 sets per session depending on pain  
Progression*: Eyes closed, bouncing ball against wall, bouncing 
ball against wall on an unstable surface 
Patellar bracing** Patient was asked to put on knee brace during ADL  
Activity modification  Activity reduction to fit within envelope of function locally 
determined and negotiated with individual patient 
WEAK AND TIGHT SUBGROUP 
CKC strengthening exercises Plie/lunge/single limb squat  
Pain free ROM  
10 reps per set/ 1-3 sets depending on pain 
Gastrocnemius and Quadriceps Stretching exercises 30 seconds static stretch x 3 reps x 1 per day 
 
Weight management strategies Locally determined and negotiated with individual patient 
WEAK AND PRONATED FOOT SUBGROUP 
CKC strengthening exercises Plie/lunge/single limb squat  
Pain free ROM  
10 reps per set/ 1-3 sets depending on pain 
Foot orthoses Custom made insole supporting medial longitudinal arch of 
foot*** 
Activity modification Improve activity levels locally determined and negotiated with 
individual patient  
 
ADL: Activity of Daily Life CKC: Closed Kinetic Chain 392 
*Progression timing in balance exercise was decided by clinician based on patient pain free achievement  393 
  ** Off the shelf knee support with patellar pad was used (Orthocare© material: 5mm neoprene /SBR /nylon jersey/pk). Brace 394 
size was selected by clinician according to patient comfort and patellar coherence (S/M/L/XL sizes were used) 395 
   *** Custom Made Insoles are tailored individually based on static and dynamic examination of load distribution on foot. 396 
using CAT-CAM free step V.1.3.30 397 
 398 
 399 
 400 
401 
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Table 3 Demographic data of patients who participated in the study 402 
 403 
PATIENTS (N=61)  MEAN SD 
AGE (YEAR) 27                                            9               
HEIGHT (CM) 170 8 
WEIGHT (KG) 65 13 
TIME SINCE SYMPTOMS STARTED 
(MO) 
24                          28 
 BMI (KG/M2) 22.5 3 
 404 
 405 
Table 4. Perception of recovery after treatments 406 
 407 
 
PHASE 1  
MULTIMODAL TREATMENT 
(N=61) 
PHASE 2  
TARGETED TREATMENT 
(N=40) 
PRS 
Overall 
% (n) 
Weak and 
Tight 
%  (n) 
Weak and 
Pronated %  
(n) 
Strong 
%  (n) 
Overall 
%  (n) 
Weak and 
Tight 
%  (n) 
Weak  and 
Pronated %  
(n) 
Strong 
%  (n) 
FULLY IMPROVED 11 (7) 16 (4) - 9 (2) 7.5 (3) 8 (1) - 11( 2) 
GREAT 
IMPROVEMENT 
23 (14) 36 (9) 29 (4) 9 (2) 65 (26) 92 (11) 80 (8) 39 (7) 
SOME 
IMPROVEMENT 
48 (29) 36 (9) 57 (8) 55(12) 17.5 (7) - 20 (2) 28 (5) 
NO CHANGE 16 (10) 12 (3) 14 (2) 18 (4) 10 (4) - - 22 (4) 
A LITTLE WORSE 4   (3) - - 9 (2) 0 (0) - - - 
 408 
 409 
 410 
 411 
 412 
 413 
 414 
 415 
 416 
 417 
 418 
 419 
 420 
 421 
 422 
 423 
 424 
 425 
 426 
 427 
 428 
 429 
 430 
 431 
 432 
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Table 5. Outcome measures differences in targeted treatment 433 
 434 
*p<0.05, VAS: Visual Analog Scale, S-LANSS: The Leeds Assessment of Neuropathic Symptoms and Signs, EQ5DL: 435 
European Quality 5 Dimension, °: degree 436 
 437 
 438 
 439 
 440 
 441 
 442 
 443 
 444 
 445 
 446 
 447 
 448 
 449 
 450 
 
 
 
 
Before Targeted 
Treatment 
 
After Targeted      
Treatment 
 
 
Outcome Measures (n=40) 
 
Median 
 
Min-Max 
 
Median 
 
Min-Max 
 
Z 
 
p 
Perception of recovery 3 3 - 5 2 1 - 4 -5,034 <0.001* 
VAS activity (cm) 4.4 0.1 - 8.8 1.8 0 - 7.5 -4.075 <0.001* 
VAS rest (cm) 1.7 0 - 7.4 0.5 0 - 7.0 -3.599 <0.001* 
S-LANSS 5 0 - 16 0 0 - 24 -3.449 0.001* 
EQ5D-5L 7 5 - 10 6 5 - 11 -3.704 <0.001* 
EQ5D-VAS 80 30 - 95 85 50 - 100 -2.322 0.020* 
Quadriceps muscle strength 
(Nm/kg) 
1,1 0,5- 2,1 1,2 0,6 – 2,3 -3.644 <0.001* 
Hip abductor muscle strength 
(Nm/kg) 
1,3 0.7 – 2,6 1,3 0,6 – 1,9 -1.456 0.145 
Patellar mobility test (mm) 12 7 - 25 11 2 - 18 -2.062 0.039* 
Foot posture index 6 0 - 11 6 0 - 12 -0.372 0.710 
Quadriceps length (0) 142.7 115 - 156 145.2 128 - 155 -2.150 0.032 
Gastrocnemius length (0) 19.6 8 - 40 20.5 12.3 - 40 -1.358 0.174 
Jump (cm) 90.2 30 - 180 91 38 - 179 -1.472 0.141 
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Table 6. Differences in subgroups before and after targeted treatment (n=40) 451 
 452 
 BEFORE TREATMENT AFTER TREATMENT Z P 
 Median Min-Max Median Min-Max   
VAS IN 
ACTIVITY  
Weak and 
Pronated (n=10) 
5.3 0.5 – 8.8 2.7 0.2 – 6.6 -1.886 
 
0.059 
Weak and Tight 
Group (n=12) 
3.7 0.4 – 7.7 3 0 – 6.5 -1.883 
 
0.060 
Strong Group 
(n=18) 
5.0 0.1- 8.2 2.0 0 – 7.5 -2.741 0.006* 
VAS AT  REST Weak and 
Pronated (n=10) 
3.9 0 – 7.1 0.8 0 – 3.4 -2.547 
 
0.011* 
Weak and Tight 
Group (n=12) 
1.0 0- 3.5 0.68 0 – 1.6 -2.667 
 
0.008* 
Strong Group 
(n=18) 
1.8 0 – 7.4 0.7 0 – 7 -1.161 
 
0.245 
PRS  Weak and 
Pronated (n=10) 
3 3-4 2 2-3 -2.887 
 
0.004* 
 
Weak and Tight 
Group 
(n=12) 
3 3-4 2 1-2 -3.213 
 
0.001* 
 
Strong Group 
(n=18) 
3 3-5 2.5 1-4 -2.830 
 
0.005* 
 
*p<0.05, VAS: Visual Analog Scale, PRS: Perception of Recovery Scale  453 
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Table 7. Outcome measures in subgroups before and after targeted treatment 
 
*p<0.05, VAS: Visual Analog Scale, LANSS: The Leeds Assessment of Neuropathic Symptoms and Signs, EQ5DL: European Quality 5 Dimension, °: degree
 Weak and Tight subgroup (n=12) Weak and Pronated subgroup (n=10) Strong subgroup (n=18) 
 
Before 
Median (Min-
Max) 
After 
Median (Min-
Max) 
 
Z 
 
p 
Before 
Median (Min-
Max) 
After 
Median (Min-
Max) 
 
Z 
 
p 
Before 
Median (Min-
Max) 
After 
Median (Min-Max) 
 
Z 
 
p 
S-LANSS 5 (0- 11) 0 (0 – 6) -2.716 0.007* 6 (0-11) 0 (0 – 10) -2.410 0.016* 5 (0- 169) 1.5 (0 – 24) -0.947 0.344 
EQ5D-5L 7.5  (5-10) 6 (5– 9) -2.556 0.011* 9 ( 6- 9) 6 (5– 11) -2.203 0.028* 6 (5-10) 6 (5– 10) -1.613 0.107 
EQ5D-VAS 80 (50- 90) 90 (50-95) -2.034 0.042* 80  (50- 90) 80  (50-100) -1.027 0.305 82.5  (30- 95) 82.5  (55-100) -1.444 0.149 
Quadriceps muscle 
strength (Nm/kg) 
0.84 (0.5-.1.3) 1.05 (0.6 – 1.4) -3.061 0.002* 1.06 (0,6-2.1) 1.3 (0.7 – 1.6) -1.887 0.059 1.2 (0.9 – 1.6) 1.2 (0.9 – 2.2) -0,893 0.372 
Hip abductor muscle 
strength (Nm/kg) 
0.9 (0.7 – 1.4) 1.1  (0.6 –1.6) -1,844 0.065 1.1 (0.7– 1.6) 1.2 (0.9– 1.6) -0.593 0.553 1.4 (0.9– 2.6) 1.5 (1 –1.9) -0.259 0.796 
Patellar mobility test 
(mm) 
10 (7- 15) 10 (8- 15) -0.103 0,918 15 (11- 22) 12 (2- 18) -2.325 0.020* 12 (8- 25) 11 (7- 17) -0.803 0,422 
Foot posture index 5 (0-9) 5.5 (2-10) -1.725 0.084 7.5 (4-11) 7.5 (2-12) -0.679 0.497 5 (0-11) 6 (0-12) -0.178 0.859 
Quadriceps length 
(0) 
137 (115 – 149) 140 (128 -152) -2.134 0.033* 140 (118 – 152) 146 (130 -155) -1.481 0.139 147 (117 – 155) 148 (128 -155) -0.071 0.943 
Gastrocnemius 
length (0) 
18.2 (10-26) 17.4 (12.6-27) -1.295 0.195 21.3 (10-40) 17.3 (12.6-34) -1.244 0.214 19.6 (8-27) 21.5 (12.3-40) -2.120 0.034* 
Jump test (cm) 79.1 (30-115) 81 (38-115) -1.718 0.286 85.4 (40-149) 84.2 (65-154) -1.718 0.086 104.5 (49.3-180.6) 107.2 (57.3-179.3) -0.305 0.760 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
